{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:36Z","timestamp":1793726016438,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Natural Science Foundation Key International","award":["81620108010"],"award-info":[{"award-number":["81620108010"]}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23NS085049"],"award-info":[{"award-number":["K23NS085049"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.expneurol.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T23:41:14Z","timestamp":1542930074000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients"],"prefix":"10.1016","volume":"312","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-3728","authenticated-orcid":false,"given":"Yingkai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vern C.","family":"Juel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa D.","family":"Hobson-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2018.11.006_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/TP.0000000000000717","article-title":"Differential effects of calcineurin and mammalian target of rapamycin inhibitors on alloreactive Th1, Th17, and regulatory T cells","volume":"99","author":"Gallon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0035","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-cell genomics unveils critical regulators of Th17 cell pathogenicity","volume":"163","author":"Gaublomme","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0040","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis","volume":"23","author":"Guptill","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0045","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody Myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0065","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-017-01571-8","article-title":"Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis","volume":"8","author":"Hu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0080","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2018.11.006_bb0085","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1007\/s10875-014-0040-5","article-title":"Unexpected targets and triggers of autoimmunity","volume":"34","author":"Lee","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trim.2017.09.005","article-title":"Impact of immunosuppressive drugs on circulating Tfh cells in kidney transplant recipients: a pilot study","volume":"46","author":"Li","year":"2018","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.12.001","article-title":"Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis","volume":"256","author":"Luo","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1196\/annals.1254.032","article-title":"T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"998","author":"Milani","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of Myasthenia gravis\u2014a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0120","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri1840","article-title":"Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases","volume":"6","author":"Pantaleo","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0135","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14656566.2013.751374","article-title":"Tacrolimus in transplant rejection","volume":"14","author":"Rath","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0150","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imr.12411","article-title":"T follicular regulatory cells","volume":"271","author":"Sage","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2496","article-title":"The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood","volume":"14","author":"Sage","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0165","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1172\/JCI76861","article-title":"Circulating T follicular regulatory and helper cells have memory-like properties","volume":"124","author":"Sage","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0175","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.it.2014.06.002","article-title":"Phenotype and functions of memory Tfh cells in human blood","volume":"35","author":"Schmitt","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol. Today"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0195","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10072-016-2769-5","article-title":"Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis","volume":"38","author":"Tao","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0205","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.143.2.718","article-title":"The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes","volume":"143","author":"Tocci","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2016.08.003","article-title":"T follicular helper cells in human autoimmunity","volume":"43","author":"Ueno","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0215","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0220","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0225","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00005-015-0362-x","article-title":"Targeting Th17 effector cytokines for the treatment of autoimmune diseases","volume":"63","author":"Yamagata","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0235","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123546","article-title":"Differential cytokine changes in patients with Myasthenia Gravis with Antibodies against AChR and MuSK","volume":"10","author":"Yilmaz","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.expneurol.2018.11.006_bb0245","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2018.11.006_bb0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618303765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618303765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:52:17Z","timestamp":1694087537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488618303765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":50,"alternative-id":["S0014488618303765"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2018.11.006","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}